Tables
-
表1
Linezolid AUC0–24, cumulative dose, and days of exposure to linezolid for patients with and without linezolid-related adverse events
Patients# Linezolid AUC0–24mg·h·L−1 p-value Linezolid cumulative dose mg·kg−1 p-value Total linezolid exposure days p-value Anaemia¶ 是的 9 (16) 158 (117–218) 0.299 918 (550–1964) 0.480 97 (52–159) 0.768 No 30 (52) 128 (98–170) 1211 (855–1830) 97 (66–150) Leukopenia+ 是的 5 (9) 158 (134–178) 0.314 1898 (1056–2668) 0.194 150 (102–352) 0.065 No 40 (69) 122 (89–171) 1046 (739–1813) 86 (62–150) Peripheral neuropathy 是的 11 (19) 149 (104–185) 0.261 1829 (1414–2255) 0.041 159 (120–196) 0.003 No 25 (43) 107 (91–156) 1164 (755–1922) 97 (66–147) Optical neuropathy 是的 1 (2) 100 0.612 997 0.735 89 0.766 No 48 (83) 127 (96–169) 1306(861–1985) 105 (67–169) Data are presented as n (%) or median (interquartile range), unless otherwise stated. Linezolid AUC0–24: area under the linezolid time–concentration curve from 0–24 h. Mann–Whitney U test was used to test whether the distribution of parameters was the same across groups with or without anaemia, leukopenia, peripheral neuropathy, and optical neuropathy respectively.#: total number of patients in the study N=58;¶: anaemia was classified for males as <8.7 mmol·L−1and for females as <7.5 mmol·L−1;+: leukopenia was classified for both males and females as <4×109·L−1.
Additional Files
-
Disclosures